Anlotinibinduced acute myocardial infarction: A case report and literature review

Anlotinib hydrochloride is a multitarget tyrosine kinase inhibitor, which has been recently approved for the treatment of advanced nonsmall cell lung cancer in China. One of its mechanisms of action is the inhibition of angiogenesis and it is similar to other antiangiogenesis drugs, as it has cardiovascular toxicity, which may damage vascular endothelial cells and result in hypertension and hyperlipidemia. All of the aforementioned factors are considered risk factors for coronary heart disease; however, the risk of developing acute myocardial infarction (AMI) has not been assessed by any previous clinical trials and subsequent research. The present case study, to the best of our knowledge, was the first to report on a patient who developed hypertension, hyperlipidemia and angina pectoris, and eventually experienced AMI, following treatment with anlotinib. This indicates that patients receiving anlotinib may require further observation and monitoring during use.